166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/ 2 trials

Sergio Giralt, William Bensinger, Mark Goodman, Donald Podoloff, Janet Eary, Richard Wendt, Raymond Alexanian, Donna Weber, David Maloney, Leona Holmberg, Joseph Rajandran, Hazel Breitz, Richard Ghalie, Richard Champlin

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Holmium-166 1, 4, 7, 10-tetraazcyclododecane-1, 4, 7, 10-tetramethylenephosphonate (166Ho-DOTMP) is a radiotherapeutic that localizes specifically to the skeleton and can deliver high-dose radiation to the bone and bone marrow. In patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation two phase 1/2 dose-escalation studies of high-dose 166Ho-DOTMP plus melphalan were conducted. Patients received a 30 mCi (1.110 Gbq) tracer dose of 166Ho-DOTMP to assess skeletal uptake and to calculate a patient-specific therapeutic dose to deliver a nominal radiation dose of 20, 30, or 40 Gy to the bone marrow. A total of 83 patients received a therapeutic dose of 166Ho-DOTMP followed by autologous hematopoietic stem cell transplantation 6 to 10 days later. Of the patients, 81 had rapid and sustained hematologic recovery, and 2 died from infection before day 60. No grades 3 to 4 nonhematologic toxicities were reported within the first 60 days. There were 27 patients who experienced grades 2 to 3 hemorrhagic cystitis, only 1 of whom had received continuous bladder irrigation. There were 7 patients who experienced complications considered to be caused by severe thrombotic microangiopathy (TMA). No cases of severe TMA were reported in patients receiving in 166Ho-DOMTP doses lower than 30 Gy. Approximately 30% of patients experienced grades 2 to 4 renal toxicity, usually at doses targeting more than 40 Gy to the bone marrow. Complete remission was achieved in 29 (35%) of evaluable patients. With a minimum follow-up of 23 months, the median survival had not been reached and the median event-free survival was 22 months. 166Ho-DOTMP is a promising therapy for patients with multiple myeloma and merits further evaluation.

Original languageEnglish
Pages (from-to)2684-2691
Number of pages8
JournalBlood
Volume102
Issue number7
DOIs
StatePublished - Oct 1 2003
Externally publishedYes

Fingerprint

Peripheral Blood Stem Cell Transplantation
Melphalan
Stem cells
Multiple Myeloma
Blood
Bone
Dosimetry
Toxicity
Holmium
Thrombotic Microangiopathies
Bone Marrow
Hematopoietic Stem Cell Transplantation
Irrigation
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)
Recovery
Radiation
Cystitis
Skeleton
Disease-Free Survival
Urinary Bladder

ASJC Scopus subject areas

  • Hematology

Cite this

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma : Results of two phase 1/ 2 trials. / Giralt, Sergio; Bensinger, William; Goodman, Mark; Podoloff, Donald; Eary, Janet; Wendt, Richard; Alexanian, Raymond; Weber, Donna; Maloney, David; Holmberg, Leona; Rajandran, Joseph; Breitz, Hazel; Ghalie, Richard; Champlin, Richard.

In: Blood, Vol. 102, No. 7, 01.10.2003, p. 2684-2691.

Research output: Contribution to journalArticle

Giralt, S, Bensinger, W, Goodman, M, Podoloff, D, Eary, J, Wendt, R, Alexanian, R, Weber, D, Maloney, D, Holmberg, L, Rajandran, J, Breitz, H, Ghalie, R & Champlin, R 2003, '166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/ 2 trials', Blood, vol. 102, no. 7, pp. 2684-2691. https://doi.org/10.1182/blood-2002-10-3250
Giralt, Sergio ; Bensinger, William ; Goodman, Mark ; Podoloff, Donald ; Eary, Janet ; Wendt, Richard ; Alexanian, Raymond ; Weber, Donna ; Maloney, David ; Holmberg, Leona ; Rajandran, Joseph ; Breitz, Hazel ; Ghalie, Richard ; Champlin, Richard. / 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma : Results of two phase 1/ 2 trials. In: Blood. 2003 ; Vol. 102, No. 7. pp. 2684-2691.
@article{7c3f8409e2b14202a8c773ab76ecb58e,
title = "166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/ 2 trials",
abstract = "Holmium-166 1, 4, 7, 10-tetraazcyclododecane-1, 4, 7, 10-tetramethylenephosphonate (166Ho-DOTMP) is a radiotherapeutic that localizes specifically to the skeleton and can deliver high-dose radiation to the bone and bone marrow. In patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation two phase 1/2 dose-escalation studies of high-dose 166Ho-DOTMP plus melphalan were conducted. Patients received a 30 mCi (1.110 Gbq) tracer dose of 166Ho-DOTMP to assess skeletal uptake and to calculate a patient-specific therapeutic dose to deliver a nominal radiation dose of 20, 30, or 40 Gy to the bone marrow. A total of 83 patients received a therapeutic dose of 166Ho-DOTMP followed by autologous hematopoietic stem cell transplantation 6 to 10 days later. Of the patients, 81 had rapid and sustained hematologic recovery, and 2 died from infection before day 60. No grades 3 to 4 nonhematologic toxicities were reported within the first 60 days. There were 27 patients who experienced grades 2 to 3 hemorrhagic cystitis, only 1 of whom had received continuous bladder irrigation. There were 7 patients who experienced complications considered to be caused by severe thrombotic microangiopathy (TMA). No cases of severe TMA were reported in patients receiving in 166Ho-DOMTP doses lower than 30 Gy. Approximately 30{\%} of patients experienced grades 2 to 4 renal toxicity, usually at doses targeting more than 40 Gy to the bone marrow. Complete remission was achieved in 29 (35{\%}) of evaluable patients. With a minimum follow-up of 23 months, the median survival had not been reached and the median event-free survival was 22 months. 166Ho-DOTMP is a promising therapy for patients with multiple myeloma and merits further evaluation.",
author = "Sergio Giralt and William Bensinger and Mark Goodman and Donald Podoloff and Janet Eary and Richard Wendt and Raymond Alexanian and Donna Weber and David Maloney and Leona Holmberg and Joseph Rajandran and Hazel Breitz and Richard Ghalie and Richard Champlin",
year = "2003",
month = "10",
day = "1",
doi = "10.1182/blood-2002-10-3250",
language = "English",
volume = "102",
pages = "2684--2691",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma

T2 - Results of two phase 1/ 2 trials

AU - Giralt, Sergio

AU - Bensinger, William

AU - Goodman, Mark

AU - Podoloff, Donald

AU - Eary, Janet

AU - Wendt, Richard

AU - Alexanian, Raymond

AU - Weber, Donna

AU - Maloney, David

AU - Holmberg, Leona

AU - Rajandran, Joseph

AU - Breitz, Hazel

AU - Ghalie, Richard

AU - Champlin, Richard

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Holmium-166 1, 4, 7, 10-tetraazcyclododecane-1, 4, 7, 10-tetramethylenephosphonate (166Ho-DOTMP) is a radiotherapeutic that localizes specifically to the skeleton and can deliver high-dose radiation to the bone and bone marrow. In patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation two phase 1/2 dose-escalation studies of high-dose 166Ho-DOTMP plus melphalan were conducted. Patients received a 30 mCi (1.110 Gbq) tracer dose of 166Ho-DOTMP to assess skeletal uptake and to calculate a patient-specific therapeutic dose to deliver a nominal radiation dose of 20, 30, or 40 Gy to the bone marrow. A total of 83 patients received a therapeutic dose of 166Ho-DOTMP followed by autologous hematopoietic stem cell transplantation 6 to 10 days later. Of the patients, 81 had rapid and sustained hematologic recovery, and 2 died from infection before day 60. No grades 3 to 4 nonhematologic toxicities were reported within the first 60 days. There were 27 patients who experienced grades 2 to 3 hemorrhagic cystitis, only 1 of whom had received continuous bladder irrigation. There were 7 patients who experienced complications considered to be caused by severe thrombotic microangiopathy (TMA). No cases of severe TMA were reported in patients receiving in 166Ho-DOMTP doses lower than 30 Gy. Approximately 30% of patients experienced grades 2 to 4 renal toxicity, usually at doses targeting more than 40 Gy to the bone marrow. Complete remission was achieved in 29 (35%) of evaluable patients. With a minimum follow-up of 23 months, the median survival had not been reached and the median event-free survival was 22 months. 166Ho-DOTMP is a promising therapy for patients with multiple myeloma and merits further evaluation.

AB - Holmium-166 1, 4, 7, 10-tetraazcyclododecane-1, 4, 7, 10-tetramethylenephosphonate (166Ho-DOTMP) is a radiotherapeutic that localizes specifically to the skeleton and can deliver high-dose radiation to the bone and bone marrow. In patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation two phase 1/2 dose-escalation studies of high-dose 166Ho-DOTMP plus melphalan were conducted. Patients received a 30 mCi (1.110 Gbq) tracer dose of 166Ho-DOTMP to assess skeletal uptake and to calculate a patient-specific therapeutic dose to deliver a nominal radiation dose of 20, 30, or 40 Gy to the bone marrow. A total of 83 patients received a therapeutic dose of 166Ho-DOTMP followed by autologous hematopoietic stem cell transplantation 6 to 10 days later. Of the patients, 81 had rapid and sustained hematologic recovery, and 2 died from infection before day 60. No grades 3 to 4 nonhematologic toxicities were reported within the first 60 days. There were 27 patients who experienced grades 2 to 3 hemorrhagic cystitis, only 1 of whom had received continuous bladder irrigation. There were 7 patients who experienced complications considered to be caused by severe thrombotic microangiopathy (TMA). No cases of severe TMA were reported in patients receiving in 166Ho-DOMTP doses lower than 30 Gy. Approximately 30% of patients experienced grades 2 to 4 renal toxicity, usually at doses targeting more than 40 Gy to the bone marrow. Complete remission was achieved in 29 (35%) of evaluable patients. With a minimum follow-up of 23 months, the median survival had not been reached and the median event-free survival was 22 months. 166Ho-DOTMP is a promising therapy for patients with multiple myeloma and merits further evaluation.

UR - http://www.scopus.com/inward/record.url?scp=0141593495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141593495&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-10-3250

DO - 10.1182/blood-2002-10-3250

M3 - Article

C2 - 12730103

AN - SCOPUS:0141593495

VL - 102

SP - 2684

EP - 2691

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -